3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasms
5
Glioblastoma
4
Lung Neoplasms
3
Carcinoma, Hepatocellular
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Glioma
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Thyroid Nodule
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pleural Neoplasms
1
Pancreatic Cyst
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Mesothelioma
1
Medication Adherence
1
Margins of Excision
1
Lymphedema
1
Lung Diseases
1
Liver Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Early-stage Peripheral Non-small Cell Lung Cancer
1
Interventions
Pemetrexed
39
Cisplatin
33
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Imatinib Mesylate
3
Cerebral Decortication
3
tislelizumab
2
sargramostim
2
fludarabine phosphate
2
defactinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mesothelioma
×
Drug Delivery Systems
×
Clear all
NCT00748085
2015-07-23
ICEtheMAD
CSA Medical, Inc.
Phase NA
Terminated
5 enrolled
5 charts